Technology is one of the greatest invention of mankind and has gifted human beings with various boons. But with the advent of time technological advancement emerged as a great threat to human civilization. Technology provides wide benefits —catching serial killers, space exploration, diagnosing cancer, — but algorithms designed for one intention can be easily used for a direful one. For instance, gene editing technology called CRISPR (Clustered, Regularly Interspaced, Short Palindromic Repeat) is a breakthrough in healthcare industry, though it is commendable, it is feared that its deliberate or unintentional misuse might lead to far-reaching economic and national security implications. One of the major threats emerged with the introduction of CRISPR is the production of biological weapons. The ease of accessibility of this technology made bioweapons extremely cheaper as compared to missiles or other hi-tech warfare equipment. Considering the harmful impacts of bioweapons, governments across the world are investing in R&D activities to seek out methods to acknowledge diseases released by biological weapons such as smallpox, plague, cholera, and anthrax. Antibody vaccines effectively induce the desired medication with comparatively higher rates of success, leading to development of monoclonal antibodies (mAbs), which target a specific area or cell.

Monoclonal antibodies (mAbs) are designed by hybridoma technology with an aim to trigger natural immune system. It is a flagship innovation in the molecular biology approved by the U.S. Food and Drug Administration (FDA) as an effective measure for disease treatment. In 2018, the global monoclonal antibodies market size valued at $101 billion and the growth is expected to propel at a CAGR of 8.5%, during the forecast period 2019-2025.


Oncology Segment dominating the Monoclonal Antibodies Market Growth—

The growth in monoclonal antibodies market size is attributed to various factors such as increasing demand for antibodies to treat several health issues like respiratory diseases, oncology, autoimmune diseases, microbial diseases, inflammatory diseases, and ophthalmology disorders. Oncology segment is expected to generate major revenue in the monoclonal antibodies market, the key application segment is poised to propel at a CAGR of 8.67% through to 2025, owing to increasing incidences of cancer. Cancer is one of the leading causes of death worldwide, which has driven the focus on early detection and treatment of disease. According to Cancer Research UK, there were around 17 million new cases of cancer in 2018, and 9.6 million deaths worldwide in 2018. The monoclonal antibodies cancer treatment stimulate the immune system to attack and destroy diseased cells. The monoclonal antibodies therapy adhere themselves to cancer cells, facilitating a simpler way for immune cells to spot diseased cells.

Multifarious Applications of Monoclonal Antibodies—

The significant role of mAbs in organ transplantations, analyzing bodily fluids for diagnosis, cardiovascular detection, and diagnosis of infectious diseases agents like HIV, and cause of AIDS are supporting the market growth. Additionally mAbs are eminent components in home-testing kits for determining ovulation, pregnancy, and menopause. They are also used to detect viruses in plants and animals; and in environmental pollution monitoring. Moreover, prominent benefits associated with monoclonal antibodies is that they can be developed in low investment and on a large-scale. Thus, these factors are expected to create burgeoning demand of monoclonal antibodies.

Major developments in Monoclonal Antibodies Market—

·         On 20 September 2017, Nivolumab (Opdivo) a monoclonal antibody drug, was made available for NHS patients with advanced lung cancer.

·         A 33-year old man suffering from schizophrenia is the first person treated by using monoclonal antibody drug at King’s College Hospital in London on 3 November 2017.

·         On 20 September 2017, an amalgamation of three monoclonal antibodies was developed which is intended to protect monkeys from HIV.       

Monoclonal Antibodies Market Leveraging Europe Region—

Europe held major share in the global monoclonal antibiotics market, accounting to 42.3% in 2018. This is mainly attributed to high incidence rate of cancer in this region. According to the World Health Organization (WHO), there are more than 3.7 million new cancer cases and 1.9 million deaths each year. Cancer represents as the second most cause of death and morbidity in Europe. Additionally, increasing R&D activities to introduce advanced production methods for mAbs in countries such as the Netherlands, Switzerland, Denmark, Germany, and others is significantly contributing to growth of the European market. Growing consumer awareness about various benefits and applications of mAb including detecting and killing abnormal cells directly, delivering radioactive particles or chemo drugs to specific cells, thereby minimizing the risk of side-effects from medication while also triggering the immune system, is also a major driving factor for the market growth. Moreover, presence of major pharmaceuticals companies such as GlaxoSmithKline plc, Novartis AG, and F. Hoffmann-La Roche Ltd. have rendered Europe with the maximum market share.

Monoclonal Antibodies Market Company Strategies—

Major companies striving to mark their presence in the global monoclonal antibodies market include Pfizer, Inc., Merck & Co., Inc., Amgen, Inc., GlaxoSmithKline plc, Abbott Laboratories, AstraZeneca, Novartis AG, Eli Lilly and Company, Mylan N.V., Bayer AG, Bristol Myers Squibb Co., Daiichi Sankyo Company, Ltd., Biogen Inc., Thermo Fisher Scientific, Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Sanofi Genzyme, and others. These companies are focusing on investing in R&D activities to innovate different monoclonal antibodies to treat various diseases.


·    In July 2019, GlaxoSmithKline plc announced the UK trial of subscription-style payment system for pharmaceutical companies to emerge in the development of new antibiotics. It also announced the start of Phase 3 program for the development of anti GM-CSF monoclonal antibody for the treatment of moderate to severe rheumatoid arthritis (RA).


·   In 2018, Thermo Fisher Scientific entered in collaboration with Symphogen, an antibody development company for two years. With this tie-up Symphogen is instigated to use liquid chromatography-tandem mass spectrometry system of Thermo Scientific to develop, inspect and confirm the platform workflows for mass analysis of therapeutic monoclonal antibody mixtures.

Talk to one of our sales representative about the full report by providing your details in the link below:


Related Reports:

 a)      Antibody Production Market

 b)     Biosimilar Monoclonal Antibody Market

Any other custom requirements can be discussed with our team, drop an e-mail to [email protected]  to discuss more about our consulting services.

To request for a quote, provide your details in the below link:

Media Contact:

Mr. Venkat Reddy

Sales Manager          

Email 1: [email protected]

Contact Sales: +1-614-588-8538 (Ext-101)

About IndustryARC: IndustryARC is a research and consulting firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.